Table 4 study characteristics in pharmacological cohort studies and in non pharmacological cohort studies
From: Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature
Study characteristics | Pharmacological cohort studies (n = 89) | Non pharmacological cohort studies (n = 61) | p-value* |
|---|---|---|---|
Sample size, Median(Interquartile range) | 3434(490–20,482) | 1041(151–2714) | <0.001 |
Length of follow up (years), Median(Interquartile range) | 4(1.7–8.3) | 3(1–6) | 0.14 |
Date of publication | 0.67 | ||
2000–2013 | 44(49) | 27(45) | |
2014–2016 | 45(51) | 34(55) | |
Journal type, n(%) | 0.74 | ||
High impact factor journals (HIJ) | 45(51.1) | 29(48) | |
Low impact factor journals (LIJ) | 44(48.9) | 32(52) | |
Study area, n(%) | |||
Non pharmacological | – | 61(100) | |
Pharmacological | 89(100) | – | |
Source of funding, n(%) | 0.04 | ||
Industry | 61(68) | 39(63) | |
Other | 15(17) | 13(22) | |
NA | 13(15) | 9(15) | |
Type of primary outcome, n(%) | 0.37 | ||
Time to event | 42(47) | 24(39) | |
Binary | 30(33) | 19(31) | |
Continuous | 17(20) | 18(30) | |
Main effect of primary outcome, n(%) | 0.55 | ||
Statistically significant | 53(60) | 42(68) | |
Not statistically significant | 36(40) | 19(32) | |
Newcastle-Ottawa Quality Assessment Score, n(%) | 0.5 | ||
0–3 | 3(4) | 2(3) | |
4–6 | 52(58) | 36(59) | |
7–8 | 34(38) | 23(38) | |
Analysis of predictive factors on side effects, n(%) | 1(2) | 1(2) | 0.49 |
HTE reporting | 63(71) | 24(39) | <0.001 |
Prespecification of HTE, n(%) | 59(66) | 24(100) | 0.59 |
Type of HTE analysis, n(%) | 0.40 | ||
Subgroup | 2(3) | 0(0) | |
Adjusted | 50(79) | 16(67) | |
Propension | 11(18) | 8(33) | |
Predictive variables studied, n(%) | |||
Age | 19(30) | 10(42) | 0.19 |
Sexe | 11(17) | 4(17) | 1 |
Social level | 2(3) | 2(8) | 0.33 |
Genetics | 9(14) | 3(12) | 1 |
Treatment | 53(84) | 13(54) | 0.002 |
Comorbidities | 19(30) | 11(46) | 0.13 |
Severity of disease | 9(14) | 3(12) | 0.18 |
Prognostic variables studied, n(%) | 30(48) | 21(34) | 0.77 |
Analysis of prognostic factors on side effect, n(%) | 1(2) | 1(2) | 0.52 |
Interaction test, n(%) | 20(22) | 7(11) | 0.27 |